Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content

Understanding Kaplan–Meier Curves in MS: An Overview with Dr. Barry Singer

Understanding 6‑Month CDP in MS: An Overview with Dr. Barry Singer

Understanding PIRA in MS: An Overview with Dr. Barry Singer

Episode 2: Skin Manifestation of GVHD – A multidisciplinary Perspective

Skin involvement represents the most frequent and often earliest manifestation of both acute and chronic GvHD, with significant diagnostic and therapeutic implications. In this episode, Dr. Marawan and Dr. Yousef provide a comprehensive, multidisciplinary review of clinical presentation, differential diagnosis, histopathologic correlation, NIH grading criteria, and the functional and quality-of-life impact of cutaneous GvHD. The discussion also addresses challenges in distinguishing chronic skin GvHD from autoimmune mimickers and highlights the importance of early recognition and coordinated care to optimize patient outcomes.

IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION

Eosinophilic inflammation has multiple drivers1,2

The pathophysiology of ITP stems from complex immune dysregulation drives thrombocytopenia and inflammation

Rilzabrutinib a BTK inhibitor

Complex immune dysregulation impact on QoL

Interplay between the innate and adaptive immunity

Charting New Course: The Frontier of Early Intervention and Disease Modification in AD

Early Intervention and Disease Modification in Atopic Dermatitis

Early Detection and Intervention

Early identification of autoantibodies can help predict T1D development before symptoms appear.